Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Dermatology
•
General Dermatology
What is the maximum dose or treatment course of topical steroids that you generally recommend to avoid causing systemic adverse effects?
Answer from: at Community Practice
Topical steroids cause essentially no systemic AEs. Dosing is limited by local AEs.
Sign in or Register to read more
Answer from: at Community Practice
I think you have to be careful with pediatric patients. A mid-potential topical corticosteroid may cause HPA axis suppression in younger skin for two main reasons, wider overall surface area and increased absorption through thinner skin.
Sign in or Register to read more
24922
25374
Related Questions
How do you approach a patient with stoma bag adhesive allergic contact dermatitis?
Have you noticed granulomatous reactions becoming more common with the rise in peptide-based and nano-technology topical formulations, along with increased use of resurfacing devices outside of physician oversight?
How have you employed AI-based tools in your practice and what do you foresee its role becoming?
What role does oral roflumilast play in dermatology?
What work up do you pursue for a thorough evaluation in patients that present with a potential diagnosis of dermatitis artefacta?
What work up do you pursue for splinter hemorrhages in an otherwise healthy patient?
In the era of targeted therapies, are there any specific cytokines that help guide therapy?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
Would you recommend continuing Accutane in a teenage female who has experienced a drop in calcium to 8.8 and reductions in albumin and protein levels one month into therapy?
What is the role of combination antimicrobial, antiviral, and immunomodulatory therapies in managing recurrent erythema multiforme with suspected infectious triggers?